Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Mol Cell Biol ; 13(6): 3722-33, 1993 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8098844

RESUMO

Adult vascular smooth muscle cells dedifferentiate and reenter the cell cycle in response to growth factor stimulation. Here we describe the molecular cloning from vascular smooth muscle, the structure, and the chromosomal location of a diverged homeobox gene, Gax, whose expression is largely confined to the cardiovascular tissues of the adult. In quiescent adult rat vascular smooth muscle cells, Gax mRNA levels are down-regulated as much as 15-fold within 2 h when these cells are induced to proliferate with platelet-derived growth factor (PDGF) or serum growth factors. This reduction in Gax mRNA is transient, with levels beginning to rise between 8 and 24 h after mitogen stimulation and returning to near normal by 24 to 48 h. The Gax down-regulation is dose dependent and can be correlated with the mitogen's ability to stimulate DNA synthesis. PDGF-AA, a weak mitogen for rat vascular smooth muscle cells, did not affect Gax transcript levels, while PDGF-AB and -BB, potent mitogens for these cells, were nearly as effective as fetal bovine serum. The removal of serum from growing cells induced Gax expression fivefold within 24 h. These data suggest that Gax is likely to have a regulatory function in the G0-to-G1 transition of the cell cycle in vascular smooth muscle cells.


Assuntos
Ciclo Celular/fisiologia , Genes Homeobox , Proteínas de Homeodomínio , Proteínas Musculares/genética , Músculo Liso Vascular/fisiologia , Animais , Aorta/citologia , Aorta/fisiologia , Sequência de Bases , Mapeamento Cromossômico , Clonagem Molecular , Cruzamentos Genéticos , DNA/genética , DNA/isolamento & purificação , Feminino , Fase G1 , Biblioteca Gênica , Genes Homeobox/efeitos dos fármacos , Variação Genética , Humanos , Cinética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Dados de Sequência Molecular , Muridae , Músculo Liso Vascular/citologia , Oligodesoxirribonucleotídeos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Ratos , Fase de Repouso do Ciclo Celular , Homologia de Sequência de Aminoácidos , Timidina/metabolismo
2.
Circ Res ; 87(10): 865-72, 2000 Nov 10.
Artigo em Inglês | MEDLINE | ID: mdl-11073881

RESUMO

Homeodomain-containing transcription factors are critical in the regulation of cell proliferation, differentiation, and migration, and they play an important role in organogenesis and pattern formation during embryogenesis. There is evidence that some of them are oncogenes or tumor suppressors. The cardiovascular system undergoes extensive remodeling during embryogenesis and disease states such as atherosclerosis and tumor-induced angiogenesis, and homeobox genes may play an important role in regulating these processes. Recently, homeobox genes have been detected in both vascular smooth muscle and endothelial cells, and they are implicated in pathological processes such as arterial restenosis after balloon angioplasty and tumor-induced angiogenesis. The cellular function of some of these genes is beginning to be elucidated. Therefore, we briefly review what is currently known about the involvement of homeobox transcription factors in both physiological and pathological vascular remodeling and angiogenesis.


Assuntos
Sistema Cardiovascular/metabolismo , Genes Homeobox/genética , Proteínas de Homeodomínio/metabolismo , Neovascularização Fisiológica/genética , Fatores de Transcrição/metabolismo , Sistema Cardiovascular/citologia , Sistema Cardiovascular/embriologia , Divisão Celular/genética , Movimento Celular/genética , Endotélio Vascular/citologia , Endotélio Vascular/metabolismo , Proteínas de Homeodomínio/genética , Família Multigênica , Músculo Liso Vascular/citologia , Músculo Liso Vascular/metabolismo , Neovascularização Patológica/genética , Fatores de Transcrição/genética
3.
Cancer Res ; 59(14): 3374-8, 1999 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-10416597

RESUMO

The family of vascular endothelial growth factor (VEGF) proteins include potent and specific mitogens for vascular endothelial cells that function in the lation of angiogenesis Inhibition of VEGF-induced angiogenesis either by neutralizing antibodies or dominant-negative soluble receptor, blocks the growth of primary and metastatic experimental tumors Here we report that VEGF expression is induced in Lewis lung carcinomas (LLCs) both in vitro and vivo after exposure to ionizing radiation (IR) and in human tumor cell lines (Seg-1 esophageal adenocarcinoma, SQ20B squamous cell carcinoma, T98 and U87 glioblastomas, and U1 melanoma) in vitro. The biological significance of IR-induced VEGF production is supported by our finding that treatment of tumor-bearing mice (LLC, Seg-1, SQ20B, and U87) with a neutralizing antibody to VEGF-165 before irradiation is associated with a greater than additive antitumor effect. In vitro, the addition of VEGF decreases IR-induced killing of human umbilical vein endothelial cells, and the anti-VEGF treatment potentiates IR-induced lethality of human umbilical vein endothelial cells. Neither recombinant VEGF protein nor neutralizing antibody to VEGF affects the radiosensitivity of tumor cells These findings support a model in which induction of VEGF by IR contributes to the protection of tumor blood vessels from radiation-mediated cytotoxicity and thereby to tumor radioresistance.


Assuntos
Anticorpos Monoclonais/farmacologia , Fatores de Crescimento Endotelial/antagonistas & inibidores , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Linfocinas/antagonistas & inibidores , Proteínas de Neoplasias/antagonistas & inibidores , Neoplasias Experimentais/radioterapia , Neovascularização Patológica/fisiopatologia , Radiossensibilizantes/farmacologia , Estresse Fisiológico/fisiopatologia , Adenocarcinoma/genética , Adenocarcinoma/patologia , Adenocarcinoma/radioterapia , Animais , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/radioterapia , Células Cultivadas , Meios de Cultivo Condicionados , Fatores de Crescimento Endotelial/imunologia , Fatores de Crescimento Endotelial/fisiologia , Endotélio Vascular/citologia , Neoplasias Esofágicas/genética , Neoplasias Esofágicas/patologia , Neoplasias Esofágicas/radioterapia , Feminino , Glioblastoma/genética , Glioblastoma/patologia , Glioblastoma/radioterapia , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Linfocinas/imunologia , Linfocinas/fisiologia , Melanoma/genética , Melanoma/patologia , Melanoma/radioterapia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Proteínas de Neoplasias/imunologia , Proteínas de Neoplasias/fisiologia , Transplante de Neoplasias , Neoplasias Experimentais/irrigação sanguínea , Neoplasias Experimentais/complicações , Neoplasias Experimentais/fisiopatologia , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Tolerância a Radiação/efeitos dos fármacos , Estresse Fisiológico/genética , Células Tumorais Cultivadas/metabolismo , Células Tumorais Cultivadas/efeitos da radiação , Ensaio Tumoral de Célula-Tronco , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio Vascular
4.
Cancer Res ; 58(24): 5686-9, 1998 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-9865723

RESUMO

Angiostatin, a proteolytic fragment of plasminogen, inhibits the growth of primary and metastatic tumors by suppressing angiogenesis. When used in combination with ionizing radiation (IR), angiostatin demonstrates potent antitumor synergism, largely caused by inhibition of the tumor microvasculature. We report here the temporal interaction of angiostatin and IR in Lewis lung carcinoma (LLC) tumors growing in the hind limbs of syngeneic mice. Tumors with an initial mean volume of 510 +/- 151 mm3 were treated with IR alone (20 Gy x 2 doses on days 0 and 1), angiostatin alone (25 mg/kg/day divided twice daily) on days 0 through 13, or a combination of the two as follows: (a) IR plus angiostatin (days 0 through 13); (b) IR plus angiostatin (days 0 and 1); and (c) IR followed by angiostatin beginning on the day after IR completion and given daily thereafter (days 2 through 13). By day 14, tumors in untreated control mice had grown to 6110 +/- 582 mm3, whereas in mice treated with: (a) IR alone, tumors had grown to 2854 +/- 338 mm3 (P < 0.05 compared with untreated controls); and (b) angiostatin alone, tumors had grown to 3666 +/- 453 mm3 (P < 0.05 compared with untreated controls). In combined-treatment groups, in mice treated with: (a) IR plus longer-course angiostatin, tumors reached 2022 +/- 282 mm3 (P = 0.036 compared with IR alone); (b) IR followed by angiostatin, tumors reached 2677 +/- 469 mm3 (P > 0.05 compared with IR alone); and (c) IR plus short-course angiostatin, tumors reached 1032 +/- 78 mm3 (P < 0.001 compared with IR alone). These findings demonstrate that the efficacy of experimental radiation therapy is potentiated by brief concomitant exposure of the tumor vasculature to angiostatin.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma Pulmonar de Lewis/tratamento farmacológico , Carcinoma Pulmonar de Lewis/radioterapia , Fragmentos de Peptídeos/uso terapêutico , Plasminogênio/uso terapêutico , Angiostatinas , Animais , Terapia Combinada , Esquema de Medicação , Feminino , Camundongos , Camundongos Endogâmicos C57BL , Fragmentos de Peptídeos/administração & dosagem , Plasminogênio/administração & dosagem , Fatores de Tempo , Células Tumorais Cultivadas
5.
Trends Cardiovasc Med ; 3(5): 184-90, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-21244931

RESUMO

Tissue remodeling and alterations in cellular differentiation occur in the cardiovascular system during normal development and pathologic conditions such as cardiac hypertrophy and atherosclerosis. Homeobox genes encode transcription factors that have been shown to be regulators of body-plan formation, cell growth, differentiation, and region-specific cell migration in developing embryos. Recently, several homeobox genes have been either isolated from or detected in cardiovascular tissues, and evidence suggests that some of them may have a regulatory function in the cardiovascular system. We review here what is known about the role of homeobox transcription factors in the control of development and gene expression in the cardiovascular system.

6.
Biotechniques ; 16(5): 856-8, 860-2, 865, 1994 May.
Artigo em Inglês | MEDLINE | ID: mdl-7915120

RESUMO

Much effort has been directed toward the isolation and characterization of homeobox cDNAs from numerous cell types because they encode transcription factors important to many cellular processes, including pattern formation in the embryo, cell growth and cell differentiation. Many novel homeobox cDNAs have been isolated by screening libraries by hybridization with degenerate oligonucleotides designed from conserved amino acid sequences in the third helix of the homeodomain. However, the degeneracy of the genetic code necessitates that these oligonucleotides be highly degenerate, often precluding their use as sequencing primers to rapidly determine clone identity. Here we describe a screening protocol for homeobox cDNAs that utilizes a short oligonucleotide probe with inosine residues incorporated at positions of maximum codon degeneracy. This probe specifically hybridizes to many classes of homeobox transcription factor cDNAs, but its primary advantage is that it also serves as an effective sequencing primer, which allows the investigator to rapidly determine whether the clones encode a protein of interest. In a screen of 500,000 plaques of a rat aorta cDNA library by this method, we identified 13 positive plaques of which 12 were found to contain homeobox cDNAs representing 5 distinct genes, and, using this probe, it was possible to obtain initial high-quality sequence information from every clone isolated that contained a homeodomain.


Assuntos
DNA Complementar/isolamento & purificação , Genes Homeobox , Fatores de Transcrição/genética , Animais , Sequência de Bases , Clonagem Molecular , DNA Complementar/química , Inosina , Dados de Sequência Molecular , Hibridização de Ácido Nucleico , Ratos
7.
Surgery ; 106(4): 604-9; discussion 609-10, 1989 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-2799635

RESUMO

Because absorption of cyclosporine (CyA) given orally immediately after liver transplantation is unreliable, the drug is usually given intravenously until external biliary drainage is discontinued. Intravenous CyA, however, is associated with serious side effects, making its use potentially hazardous. We report the results of a new strategy in which we used oral CyA exclusively and refed bile to enhance oral CyA absorption. Thirty-two liver transplant recipients with indwelling T tubes were studied. All were given sequential quadruple drug immunosuppression with antilymphoblast globulin, azathioprine, and steroids. Oral CyA and refeeding of bile was started when renal function was stable. By the second posttransplant week, satisfactory CyA levels were achieved, and antilymphoblast globulin therapy was stopped. There were significant associations between oral CyA dose and CyA level and between quantity of refed bile and CyA level (p less than 0.001). CyA dose and quantity of bile refed were covariates, however, and in multiple regression analysis, only the quantity of refed bile was significant (p = 0.001). CyA levels did not correlate with rejection. The incidence of rejection was 63%. At a mean follow-up of 9 months, 28/32 (88%) patients were alive, and actuarial 1-year patient survival was 84%. Current graft and renal function are excellent (serum bilirubin, 1.0 +/- 0.1 mg/dl; serum creatinine, 1.2 +/- 0.1 mg/dl). We conclude that intravenous CyA can be avoided in virtually all liver-transplant recipients by administration of oral CyA with bile in the early posttransplant period.


Assuntos
Bile , Ciclosporinas/administração & dosagem , Transplante de Fígado , Administração Oral , Doenças do Sistema Nervoso Central/induzido quimicamente , Ciclosporinas/efeitos adversos , Rejeição de Enxerto , Humanos , Injeções Intravenosas , Rim/efeitos dos fármacos , Hepatopatias/mortalidade , Hepatopatias/terapia , Testes de Função Hepática , Período Pós-Operatório
10.
J Biol Chem ; 267(36): 26085-90, 1992 Dec 25.
Artigo em Inglês | MEDLINE | ID: mdl-1361191

RESUMO

We report here the cloning of a cDNA encoding a homeobox transcription factor from vascular smooth muscle and describe its unique pattern of mRNA expression at different stages in development. The cDNA isolated is 1576 base pairs in length not including the poly(A) tail and contains an open reading frame coding for a predicted 372-amino acid homeobox protein. During early embryogenesis, expression was detected in the neural tube with a sharp expression boundary occurring at an anterior position, in the myelencephalon, in the third and fourth branchial arches, and in vessels leading from the heart. In adults, however, transcripts were only detected in aortic smooth muscle and lung but were undetectable in cardiac or skeletal muscle, visceral smooth muscle, and many other tissues including brain. In neonates, expression was detected in the outflow tracts of the heart as well as in the cardiomyocytes. The expression pattern of this gene suggests that, although it likely has multiple roles during development, in the adult, it may participate in the control of vascular smooth muscle differentiation and proliferation.


Assuntos
Envelhecimento/fisiologia , Aorta/fisiologia , Genes Homeobox , Proteínas de Homeodomínio , Músculo Liso Vascular/fisiologia , Fatores de Transcrição/genética , Sequência de Aminoácidos , Animais , Animais Recém-Nascidos , Aorta/crescimento & desenvolvimento , Sequência de Bases , Northern Blotting , Clonagem Molecular , DNA/genética , DNA/isolamento & purificação , Embrião de Mamíferos , Biblioteca Gênica , Humanos , Hibridização In Situ , Dados de Sequência Molecular , Desenvolvimento Muscular , Músculo Liso Vascular/crescimento & desenvolvimento , Oligodesoxirribonucleotídeos , Sondas RNA , RNA Mensageiro/análise , RNA Mensageiro/genética , Ratos , Ratos Sprague-Dawley , Homologia de Sequência de Aminoácidos
11.
Genes Dev ; 11(13): 1674-89, 1997 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-9224717

RESUMO

gax, a diverged homeobox gene expressed in vascular smooth muscle cells (VSMCs), is down-regulated in vitro by mitogen stimulation and in vivo in response to vascular injury that leads to cellular proliferation. Recombinant Gax protein microinjected into VSMCs and fibroblasts inhibited the mitogen-induced entry into S-phase when introduced either during quiescence or early stages of G1. Overexpression of gax with a replication-defective adenovirus vector resulted in G0/G1 cell cycle arrest of VSMCs and fibroblasts. The gax-induced growth inhibition correlated with a p53-independent up-regulation of the cyclin-dependent kinase inhibitor p21. Gax overexpression also led to an association of p21 with cdk2 complexes and a decrease in cdk2 activity. Fibroblasts deficient in p21 were not susceptible to a reduction in cdk2 activity or growth inhibition by gax overexpression. Localized delivery of the virus to denuded rat carotid arteries significantly reduced neointima formation and luminal narrowing. These data indicate that gax overexpression can inhibit cell proliferation in a p21-dependent manner and can modulate injury-induced changes in vessel wall morphology that result from excessive cellular proliferation.


Assuntos
Quinases relacionadas a CDC2 e CDC28 , Ciclinas/fisiologia , Proteínas de Homeodomínio/fisiologia , Proteínas Musculares/fisiologia , Adenoviridae/genética , Adenoviridae/fisiologia , Angioplastia com Balão/efeitos adversos , Animais , Lesões das Artérias Carótidas , Divisão Celular , Linhagem Celular , Quinase 2 Dependente de Ciclina , Inibidor de Quinase Dependente de Ciclina p21 , Quinases Ciclina-Dependentes/antagonistas & inibidores , Quinases Ciclina-Dependentes/genética , Vírus Defeituosos/genética , Vírus Defeituosos/fisiologia , Regulação da Expressão Gênica , Vetores Genéticos , Proteínas de Homeodomínio/genética , Humanos , Proteínas Musculares/genética , Músculo Liso Vascular/citologia , Músculo Liso Vascular/metabolismo , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Serina-Treonina Quinases/genética , Ratos , Proteínas Recombinantes de Fusão/genética , Proteína Supressora de Tumor p53/genética
12.
Nature ; 394(6690): 287-91, 1998 Jul 16.
Artigo em Inglês | MEDLINE | ID: mdl-9685160

RESUMO

Angiogenesis, the formation of new capillaries from pre-existing vessels, is essential for tumour progression. Angiostatin, a proteolytic fragment of plasminogen that was first isolated from the serum and urine of tumour-bearing mice, inhibits angiogenesis and thereby growth of primary and metastatic tumours. Radiotherapy is important in the treatment of many human cancers, but is often unsuccessful because of tumour cell radiation resistance. Here we combine radiation with angiostatin to target tumour vasculature that is genetically stable and therefore less likely to develop resistance. The results show an antitumour interaction between ionizing radiation and angiostatin for four distinct tumour types, at doses of radiation that are used in radiotherapy. The combination produced no increase in toxicity towards normal tissue. In vitro studies show that radiation and angiostatin have combined cytotoxic effects on endothelial cells, but not tumour cells. In vivo studies show that these agents, in combination, target the tumour vasculature. Our results provide support for combining ionizing radiation with angiostatin to improve tumour eradication without increasing deleterious effects.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma Pulmonar de Lewis/tratamento farmacológico , Carcinoma Pulmonar de Lewis/radioterapia , Fragmentos de Peptídeos/uso terapêutico , Plasminogênio/uso terapêutico , Angiostatinas , Animais , Apoptose , Carcinoma Pulmonar de Lewis/irrigação sanguínea , Terapia Combinada , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/efeitos da radiação , Feminino , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Transplante de Neoplasias , Neovascularização Patológica/tratamento farmacológico , Neovascularização Patológica/radioterapia , Proteínas Recombinantes/uso terapêutico , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA